Inhibiting GSK3β with a GSK3β inhibitor in TAMs reduces the proliferation, migration and invasion of HCC cells in vitro and inhibits tumour growth in vivo improving the sensitivity of the anti-PD1 therapy. This evidence concerns the gene GSK3B and hepatocellular carcinoma.